... also said it expects annual unreimbursed research and development costs to be higher than previously estimated. Tarrytown, N.Y.-based Regeneron commercializes medicines for eye diseases, high cholesterol and a rare inflammatory condition. The ...
http://ift.tt/2aPV9id
No comments:
Post a Comment